Diederik De Cock

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

Josef S Smolen, Robert Landewé, J. W. J. Bijlsma et al. · Annals of the Rheumatic Diseases · 2020 · 2.6K citations · Full text

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Lianne Kearsley‐Fleet, Rebecca Davies, Diederik De Cock et al. · Annals of the Rheumatic Diseases · 2018 · 159 citations · Full text

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration

Kim Lauper, Michele Iudici, Denis Mongin et al. · Annals of the Rheumatic Diseases · 2022 · 138 citations · Full text

Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial

Patrick Verschueren, Diederik De Cock, Luk Corluy et al. · Annals of the Rheumatic Diseases · 2014 · 124 citations · Full text

Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial

Patrick Verschueren, Diederik De Cock, Luk Corluy et al. · Annals of the Rheumatic Diseases · 2016 · 114 citations